Literature DB >> 27658779

Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients.

Xiaofeng Hang1, Zhiqin Wu1, Kaijian Chu2, Guanzhen Yu3, Haoran Peng4, Haiguang Xin1, Xiaohui Miao1, Junxue Wang5, Wensheng Xu6.   

Abstract

The aim of this study was to investigate the prognostic value of dicarbonyl/L-xylulose reductase (DCXR) in human hepatocellular carcinoma (HCC). Immunohistochemistry and tissue microarrays were used to evaluate DCXR protein expression levels. Image-Pro Plus was used to calculate the integral optic density (IOD) in each tissue sample, which represented the expression level of DCXR. DCXR proteins were found to be significantly lower in HCC tumor tissues (P < 0.0001) according to immunohistochemical analysis of DCXR protein levels in 74 paired HCC tissue and peritumoral non-cancer tissues. The prognostic value of DCXR in HCC was assessed in 290 cases of the training cohort and 74 cases of the validation cohort. Shorter overall survival (OS) time and shorter time to recurrence (TTR) in both the training and validation set were found to be associated with lower expression levels of DCXR. In the training set, the expression level of DCXR in HCC was an independent prognostic factor for OS according to univariate and multivariate analyses. In conclusion, DCXR expression is an independent prognostic factor for OS and TTR of post-operative HCC patients, and low expression levels of DCXR in HCC may indicate poor outcome of HCC patients after surgical resection.

Entities:  

Keywords:  Dicarbonyl/L-xylulose reductase; Hepatocellular carcinoma; Prognosis; Tissue microarray

Mesh:

Substances:

Year:  2016        PMID: 27658779     DOI: 10.1007/s13277-016-5302-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

1.  CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.

Authors:  Xin-Rong Yang; Yang Xu; Bin Yu; Jian Zhou; Jia-Chu Li; Shuang-Jian Qiu; Ying-Hong Shi; Xiao-Ying Wang; Zhi Dai; Guo-Ming Shi; Bin Wu; Li-Ming Wu; Guo-Huan Yang; Bo-Heng Zhang; Wen-Xin Qin; Jia Fan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

2.  Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital.

Authors:  C San Miguel; Y Fundora; J Triguero; K Muffak; T Villegas; A Becerra; D Garrote; J A Ferrón
Journal:  Transplant Proc       Date:  2015-10       Impact factor: 1.066

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

5.  Crystal structure of human L-xylulose reductase holoenzyme: probing the role of Asn107 with site-directed mutagenesis.

Authors:  Ossama El-Kabbani; Shuhei Ishikura; Connie Darmanin; Vincenzo Carbone; Roland P-T Chung; Noriyuki Usami; Akira Hara
Journal:  Proteins       Date:  2004-05-15

Review 6.  Hepatocellular carcinoma: A comprehensive review.

Authors:  Lisa P Waller; Vrushak Deshpande; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2015-11-18

7.  Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma.

Authors:  Jeong Hee Cho-Vega; Spiridon Tsavachidis; Kim-Anh Do; Junichi Nakagawa; L Jeffrey Medeiros; Timothy J McDonnell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

8.  The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study.

Authors:  Yi Liu; Xiwei Wang; Sanglin Li; Huaidong Hu; Dazhi Zhang; Peng Hu; Yixuan Yang; Hong Ren
Journal:  J Proteomics       Date:  2014-04-24       Impact factor: 4.044

9.  ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.

Authors:  Hye Won Hwang; Sang Yun Ha; Heejin Bang; Cheol-Keun Park
Journal:  Cancer Res Treat       Date:  2015-02-16       Impact factor: 4.679

Review 10.  Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures.

Authors:  Masahiro Tanaka; Francisco Katayama; Hideaki Kato; Hideo Tanaka; Jianbing Wang; You Lin Qiao; Manami Inoue
Journal:  J Epidemiol       Date:  2011-10-22       Impact factor: 3.211

View more
  2 in total

1.  Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.

Authors:  Kashif Rafiq Zahid; Shiming Han; Fuling Zhou; Umar Raza
Journal:  Cell Oncol (Dordr)       Date:  2018-09-20       Impact factor: 7.051

2.  Androgen-dependent alternative mRNA isoform expression in prostate cancer cells.

Authors:  Jennifer Munkley; Teresa M Maia; Nekane Ibarluzea; Karen E Livermore; Daniel Vodak; Ingrid Ehrmann; Katherine James; Prabhakar Rajan; Nuno L Barbosa-Morais; David J Elliott
Journal:  F1000Res       Date:  2018-08-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.